Biodesix, Inc. (BDSX)

Market Cap	141.47M
Revenue (ttm)	49.09M
Net Income (ttm)	-52.15M
Shares Out	114.55M
EPS (ttm)	-0.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,758
Open	1.240
Previous Close	1.260
Day's Range	1.210 - 1.240
52-Week Range	1.030 - 2.210
Beta	1.12
Analysts	Strong Buy
Price Target	3.50 (+183.4%)
Earnings Date	May 8, 2024

About BDSX

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lu...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 28, 2020
• Employees: 217
• Stock Exchange: NASDAQ
• Ticker Symbol: BDSX

Financial Performance

In 2023, Biodesix's revenue was $49.09 million, an increase of 28.46% compared to the previous year's $38.21 million. Losses were -$52.15 million, -20.32% less than in 2022.

Analyst Forecast

According to one analyst, the rating for BDSX stock is "Strong Buy" and the 12-month stock price forecast is $3.5.

Price Target

$3.5

(183.40% upside)

Analyst Consensus: Strong Buy